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Activation of peroxisome proliferator-activated receptor 𝛼 (PPAR𝛼) confers cardioprotection, while its mechanism remains elusive.
We investigated the protective effect of PPAR𝛼 activation against cardiac ischemia-reperfusion injury in terms of the expression of
uncoupling protein (UCP). Myocardial infarct size and UCP expression were measured in rats treated with WY-14643 20mg/kg,
a PPAR𝛼 ligand, or vehicle. WY-14643 increased UCP3 expression in vivo. Myocardial infarct size was decreased in the WY-14643
group (76 ± 8% versus 42 ± 12%, 𝑃 < 0.05). During reperfusion, the incidence of arrhythmia was higher in the control group
compared with the WY-14643 group (9/10 versus 3/10, 𝑃 < 0.05). H9c2 cells were incubated for 24 h with WY-14643 or vehicle.
WY-14643 increased UCP3 expression in H9c2 cells. WY-14643 decreased hypoxia-stimulated ROS production. Cells treated with
WY-14643 were more resistant to hypoxia-reoxygenation than the untreated cells. Knocking-down UCP3 by siRNA prevented
WY-14643 from attenuating the production of ROS. UCP3 siRNA abolished the effect of WY-14643 on cell viability against
hypoxia-reoxygenation. In summary, administration of PPAR𝛼 agonistWY-14643mitigated the extent ofmyocardial infarction and
incidence of reperfusion-induced arrhythmia. PPAR𝛼 activation conferred cytoprotective effect against hypoxia-reoxygenation.
Associated mechanisms involved increased UCP3 expression and resultant attenuation of ROS production.
1. Introduction
Peroxisome proliferator-activated receptor 𝛼 (PPAR𝛼), a
member of the nuclear hormone receptor superfamily, is a
transcription factor that regulates the expression of genes
involved in cellular lipid metabolism [1]. Myocardial PPAR𝛼-
overexpression increased fatty acid uptake and oxidation
with a concomitant decrease in glucose uptake and oxida-
tion [2, 3], and these metabolic changes were associated
with left ventricular hypertrophy and systolic dysfunction
[4]. In contrast, pharmacologic activation of PPAR𝛼 has
been shown to confer myocardial protection against acute
ischemia-reperfusion injury [5–7]. However, the underlying
mechanism of cardioprotection by acute PPAR𝛼 activation
remains unclear.
Uncoupling proteins (UCPs) are inner mitochondrial
carrier proteins that induce proton leak and dissipate the
mitochondrial electrochemical gradient [8]. UCP1 was firstly
discovered as a regulator of thermogenesis in brown adi-
pose tissue. UCP2 and UCP3 were found to be expressed
in various tissues including the heart while their role in
the heart is still elusive. Previous studies suggested that
UCPs may have a protective role during oxidative stress.
Mitochondrial reactive oxygen species (ROS) generation is
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known to be proportional to electrochemical gradient across
the inner membrane [9]. Mild uncoupling and decreased
proton gradient across the mitochondrial inner membrane
reduced ROS production [10]. In conjunction, dinitrophenol,
a pharmacologic uncoupling agent, exerted cardioprotective
effect [11, 12]. Overexpression of UCP2 in cardiomyocyte
attenuated ROS production and increased tolerance to oxida-
tive stress [13]. Moreover, UCP2 and UCP3 were upregulated
after ischemic preconditioning [14].
UCP3 is upregulated by circulating free fatty acid and
PPAR𝛼 has been shown to be a mediator of transcriptional
activation of UCP3 [15, 16]. Based on the regulatory role
of PPAR𝛼 in the expression of UCP, we hypothesized that
the mechanism of cardioprotective effect of PPAR𝛼 against
ischemia-reperfusion injury could involve increased expres-
sion of UCP, particularly UCP3, and resultant attenuation of
ROS generation.This study aimed to investigatewhetherWY-
14643, a PPAR𝛼 ligand, conferred protection against acute
myocardial ischemia-reperfusion injury, and the cardiopro-
tection involved upregulation of UCP3 and reduced ROS
production.
2. Materials and Methods
2.1. Animal Preparation and Experimental Protocol. This
study was approved by the institutional ethics committee
for laboratory animal experiments and all experiments were
conducted according to the Guide for the Care and Use of
Laboratory Animals (National Institutes of Health publica-
tion number 85-23, revised 1996).
Male Sprague-Dawley rats weighing 250 to 350 g were
anesthetized with sodium pentobarbital 50mg/kg i.p. bolus.
Additional intermittent bolus of sodium pentobarbital
10mg/kg every 1 h was followed for the maintenance of
anesthesia. The left jugular vein was cannulated for delivery
of fluid and Patent Blue dye. The left carotid artery was
cannulated for continuous monitoring of mean arterial
pressure (MAP) and heart rate (HR). A 3-lead electro-
cardiogram was placed for detection of ischemic change
and arrhythmia. Premature ventricular beats, ventricular
tachycardia, and ventricular fibrillation were evaluated
according to the criteria of the Lambeth convention [17].
The animals were ventilated via tracheostomy with 60%
oxygen/air mixture at a tidal volume of 8mL/kg. Respiratory
rate was initially set to 50 breaths/min and adjusted to
maintain the arterial PCO
2
between 35 and 40mmHg. The
heart was exposed via left thoracotomy and a snare was
placed around the left anterior descending coronary artery
(LAD). After the surgical preparation, all rats were stabilized
for 30min before LAD occlusion. Ischemia was induced
by tightening the snare. Ischemia was confirmed by visual
inspection of pale color on the anterior wall of the heart and
ST segment elevation on electrocardiogram. After 30min
of ischemia, myocardium was reperfused by loosening the
snare for 2 h.
Animals were randomly allocated into two groups. The
WY group received PPAR𝛼 agonist WY-14643 (4-chloro-6-
[2,3-xylidino]-2-pyrimidinylthioacetic acid, Sigma-Aldrich
Korea, Seoul, Korea) 20mg/kg i.p. 4 h before LAD occlusion
for the measurement of infarct size, or 4 h before the excision
of heart for RT-PCR and western blot analysis. The control
group received the same volume of 5% dimethyl sulfoxide
(DMSO).
2.2. Measurement of Infarct Size. The LAD was reoccluded
after 2 h of reperfusion and 2mL/kg of 10% Patent Blue was
administered via the left jugular vein. The heart was rapidly
extracted and the right ventricle was carefully removed. The
left ventricle was incubated at −20∘C for 20min. There-
after, the left ventricle was sectioned into 1–1.5mm slices
perpendicular to the apex-base axis. Then the slices were
incubated in 2% triphenyltetrazolium chloride for 30min
at 37∘C to distinguish the infarcted tissue from the viable
myocardial areas. Areas which were not stained by Patent
Blue indicated area at risk. Pale discolored areas represented
infarcted myocardium while viable myocardial areas were
stained red. Both planes of the slices were photographed and
infarct size was calculated as area of infarction/area at risk ×
100 (%).
2.3. Cell Culture. TheH9c2 cell linewas obtained fromATCC
(Manassas, VA, USA). The cells were cultured in ATCC-
formulated Dulbecco’s Modified Eagle’s Medium containing
10% fetal bovine serum at 37∘C in an atmosphere of 95% air
and 5% CO
2
, based on the manufacturer’s recommendations.
The cells were treated with WY-14643 or vehicle for 24 h
before RT-PCR, western blot, ROS measurement, or cell sur-
vival experiment. For cellular hypoxia-reoxygenation, cells
were incubated for 20 h in an anoxic chamber immediately
after the culture medium was exchanged with the medium
that was preincubated for 8 h in an anoxic chamber and
reoxygenated for 2 h with normal medium.
2.4. Gene Silencing with siRNA. Cells were seeded into 100-
mm culture dishes 18–24 h prior to transfection. Cells were
transfected with 80 nM control siRNA (Ambion, Austin,
TX, USA) and UCP3 siRNA (Genolution, Seoul, Korea), in
serum-free medium using RNAiMAX (Invitrogen, Carlsbad,
CA, USA). Following incubation for 6 h, the transfection
medium was replaced with fresh medium, and the cells
were incubated for additional 48 h, at which point they were
treated with the indicated reagents for the indicated time.
2.5. RT-PCR. Total RNA was isolated from cultured cells
using TRIzol (Invitrogen, Carlsbad, CA, USA) according to
the manufacturer’s instructions. First-strand cDNA synthesis
from 5 𝜇g of total RNA was performed using SuperScript
II reverse transcriptase (Invitrogen, Carlsbad, CA, USA)
primed by randomhexamer primer.The transcripts of UCP2,
UCP3, and GAPDH were evaluated by PCR analysis. The
PCR amplification was performed in a final reaction volume
of 50𝜇L under the following conditions: preincubation for
5min at 94∘C, 30 cycles of 30 s at 94∘C, 30 s at 58∘C, and 45 s
at 72∘C, and one final incubation for 10min at 72∘C.The PCR
products were separated by electrophoresis through 1.5%
agarose gels. For quantitative RT-PCR, an aliquot (1/40) of
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the reaction was used for quantitative PCR using the SYBR
Green PCR Master Mix (Applied Biosystems, Life Technolo-
gies Korea, Seoul, Korea) and gene-specific primers. RT-PCR
products were quantified using the ABI PRISM 7300 RT-
PCR System (Applied Biosystems, Life Technologies Korea,
Seoul, Korea). RT-PCR was performed using the following
primers: UCP2, 5󸀠-CTCCC AATGT TTGCC CGAAA-3󸀠,
5󸀠-ACTGG CCCAA GGCAG AGTTC-3󸀠; UCP3, 5󸀠-TATGG
TGCGC ACAGA GGGTC-3󸀠, 5󸀠-CACCA CATCC GTGGG
TTGAG-3󸀠; GAPDH, 5󸀠-ACCAC AGTCC ATGCC ATCAC-
3󸀠, 5󸀠-TCCAC CACCC TGTTG CTGTA-3󸀠. GAPDHmRNA
was also measured as an invariant control.
2.6. Western Blot Analysis. Cells treated with the indicated
reagents were washed in ice-cold PBS and lysed in PRO-
PREP Protein Extraction Solution (iNtRON Biotechnology,
Seoul, Korea). An aliquot of the cell lysate was subjected to
SDS-polyacrylamide gel electrophoresis and transferred onto
Hybond-P polyvinylidene difluoride membrane (Amersham
Biosciences, Corston, UK). Membranes blocked with 5%
nonfat milk in Tris-Buffered Saline (TBS) containing 0.1%
Tween-20 overnight at 4∘C were reacted with the indi-
cated specific antibodies in TBS containing 1% BSA and
0.05% Tween-20 overnight at 4∘C and then incubated with
peroxidase-conjugated goat antibody diluted to 1 : 3000 for
2 h at room temperature. After extensive washing in TBS con-
taining 0.1% BSA and 0.1% Tween-20, immunoreactive bands
were detected usingWest-ZOL Plus (iNtRONBiotechnology,
Seoul, Korea).
2.7. MTT Assay. MTT (3-[4,5-dimethylthiazol-2-yl]-
2,5 diphenyl tetrazolium bromide, final concentration
of 0.1mg/mL) was added to the culture medium, and
cells were incubated for additional 4 h. The medium was
removed and formazan crystals formed by the reduction
of MTT by mitochondrial dehydrogenases in living cells
were solubilized in acidified isopropanol and measured
spectrophotometrically at 570 nm.
2.8. Measurement of Reactive Oxygen Species. After the cells
were subjected to hypoxia or normoxia as described above,
they were incubated with 5 𝜇M 2󸀠,7󸀠-dichlorofluorescein
diacetate (DCF-DA, Calbiochem, San Diego, CA, USA) for
a final 30min, then harvested, and washed twice with ice-
cold PBS. The cells were immediately analyzed for fluores-
cence intensity using a FACSCalibur flow cytometer (Becton-
Dickinson Immunocytometry Systems, San Jose, CA, USA)
and CellQuestPro software.
Intracellular superoxide production was measured by
lucigenin-amplified chemiluminescence or a fluorescent
indicator, dihydroethidium (DHE). To determine the level of
superoxide anion by lucigenin, cells were treated with each
reagent and, then, trypsinized and collected by centrifugation
at 1,000 rpm for 5min. After washing twice with ice-cold
PBS, the cells were resuspended in HBSS buffer (5.4mM
KCl, 0.3mMNa
2
HPO
4
, 0.4mMKH
2
PO
4
, 4.2mMNaHCO
3
,
1.3mM CaCl
2
, 0.5mM MgCl
2
, 0.6mM MgSO
4
, 137mM
NaCl, and 5.6mM glucose, pH 7.4) containing 5mM of
lucigenin. The lucigenin-derived chemiluminescence was
determined every 50 s for a total of 5min, by LB96V
luminometer (EG&G Berthold, Bad Wildbad, Germany).
For analysis of intracellular superoxide production, cells
treated as described above were washed with ice-cold PBS
and incubated for 30min at 37∘Cwith 10mMof DHE in PBS.
Following incubation in a humidified chamber protected
from light, the red fluorescence was detected through a
580 nm longpass filter using a fluorescence microscope
(Olympus, Tokyo, Japan).
Mitochondrial superoxide was detected by MitoSOX
Red-based flow cytometry. After the cells were subjected to
hypoxia or normoxia as described above, theywere incubated
with 4 𝜇M MitoSOX Red superoxide indicator (Invitrogen)
for 30min at 37∘C. After centrifugation, the cell pellets were
resuspended and washed once at room temperature phenol
red-free, HEPES-buffered DMEM supplemented with 2%
dialyzed FBS. The cells were then resuspended in 750 𝜇L of
the same buffer containing 1 𝜇g/mL DAPI and kept on ice
until flow cytometric analysis.
2.9. Statistical Analysis. Values are expressed as mean ±
SD. Data were analyzed by independent 𝑡-test except the
hemodynamic variables, which were analyzed by repeated
measures of ANOVA. The incidence of arrhythmia was
compared by chi-square test. SAS (version 9.1.3, SAS Institute,
Inc., Cary, NC, USA) was used for statistical analysis. A 𝑃
value of less than 0.05 was considered statistically significant.
3. Results
3.1. Myocardial Infarct Size following LAD Occlusion. Area at
risk was similar between the groups (41 ± 6% versus 39 ±
10%, control versus WY-14643, resp., 𝑃 > 0.05, Figure 1(a)).
Myocardial infarct size was significantly smaller in the WY-
14643 group comparedwith the control group (76±8%versus
42 ± 12%, 𝑃 < 0.05, Figure 1(b)).
3.2. Effect of WY-14643 on UCP Expression In Vivo. Animals
received WY-14643 20mg/kg i.p. 4 h before excision of the
heart. UCP3mRNA expression was significantly increased in
the WY-14643 group compared with the control group (𝑃 <
0.05, Figures 2(a)-2(b)). UCP3 protein level was increased
withWY-14643 administration, and heme oxygenase-1 (HO-
1) expression, and phosphorylated Akt and Erk were also
increased (𝑃 < 0.05, Figure 2(c)). UCP2 expression did not
increase after WY-14643 administration.
3.3. Hemodynamic Variables and Incidence of Arrhythmia.
Hemodynamic variables including mean arterial pressure,
heart rate, and rate pressure product showed no significant
differences between the groups (Table 1). During reperfusion,
incidence of arrhythmia was significantly higher in the
control group compared with the WY-14643 group (9/10
versus 3/10, 𝑃 < 0.05). In the control group, ventricular
tachycardia was detected in 2 rats and premature ventricular
beats were detected in 7 rats. In the WY-14643 group,
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Table 1: Hemodynamic data during ischemia-reperfusion.
MAP (mmHg) Heart rate (beats/min) RPP (mmHg⋅beats/min)
Control WY Control WY Control WY
Baseline 94 ± 15 107 ± 11 440 ± 40 450 ± 29 41438 ± 8847 48432 ± 6877
Before ischemia 97 ± 13 94 ± 24 435 ± 43 452 ± 42 42506 ± 7402 42428 ± 10754
Before reperfusion 89 ± 23∗ 82 ± 24∗ 436 ± 62 441 ± 76 39042 ± 12347 36719 ± 15041
15min after reperfusion 77 ± 19∗ 91 ± 27∗ 401 ± 56 426 ± 57 31403 ± 11025∗ 39381 ± 13750∗
30min after reperfusion 77 ± 15∗ 88 ± 15∗ 419 ± 60 418 ± 62 32688 ± 9924∗ 37592 ± 10024∗
60min after reperfusion 75 ± 26∗ 91 ± 15∗ 419 ± 53 418 ± 60 32117 ± 13794∗ 38494 ± 8261∗
2 h after reperfusion 87 ± 17 91 ± 22 425 ± 59 405 ± 43 37259 ± 9170∗ 37268 ± 9514∗
Data are expressed as mean ± SD. ∗𝑃 < 0.05 versus baseline.
MAP: mean arterial pressure; RPP: rate pressure product; WY: WY-14643 group.
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Figure 1: WY-14643 decreased myocardial infarct size. WY-14643 20mg/kg was administered 4 h before the occlusion of left anterior
descending coronary artery. (a) Area at risk was similar between the groups. (b) WY-14643 decreased the percentage of myocardial infarct
size to area at risk. ∗𝑃 < 0.05 versus control (𝑛 = 10). (c) Representative pictures of stained myocardial sections.
ventricular tachycardiawas detected in one rat and premature
ventricular beats were detected in 2 rats.
3.4. Effect of WY-14643 on UCP Expression In Vitro. Figure 3
illustrates the expression of UCP2 andUCP3 inH9c2 cell line
after 24 h incubation in the control medium or experimental
media containing 0.1 to 100 𝜇M ofWY-14643. In cells treated
with 50 𝜇M of WY-14643, expression of PDK4 mRNA, a
PPAR𝛼 target gene, was increased. Expression of PPAR𝛾 tar-
get gene aP2 was not altered after treatment with WY-14643,
indicating that WY-14643 activated PPAR𝛼 specifically
(Figure 3(a)). Upregulation of UCP3 mRNA was observed in
cells treatedwith 10𝜇Mor greater concentration ofWY-14643
compared with the control (𝑃 < 0.05, Figures 3(b)-3(c)).
UCP3 protein increased after treatment of 10 𝜇M or greater
concentration of WY-14643 (Figure 3(d)). The expression of
UCP2 was not altered byWY-14643 treatment. Subsequently,
whetherWY-14643 activated other cardioprotective signaling
pathways was examined. Treatment of WY-14643 at 50𝜇M
increased phosphorylation of Akt and STAT3 and protein
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Figure 2: WY-14643 increased UCP3 expression in rats. WY-14643 20mg/kg was administered 4 h before the extraction of heart. (a)
Quantitative PCR shows thatWY-14643 increasedmRNA levels comparedwith vehicle. ∗𝑃 < 0.05 (𝑛 = 3). (b) RT-PCR shows increasedUCP3
mRNAexpression followingWY-14643 administration. (c)Western blot shows increased expression ofUCP3 andHO-1, and phosphorylation
of Akt and Erk afterWY-14643 administration. Band intensities were quantified using an image analyzer and normalized by expression levels
of 𝛽-actin. ∗𝑃 < 0.05 (𝑛 = 4). (d) Representative blots are shown.
level of HO-1 as well as UCP3 (Figure 3(e)). Transfection of
UCP3 siRNA silenced UCP3mRNA (Figure 3(f)), and UCP3
siRNA downregulated UCP3 protein level (Figure 3(g)).
3.5. WY-14643 Decreased Hypoxia-Stimulated ROS Produc-
tion. Assessing whether WY-14643 could reduce oxidative
stress and UCP3 upregulation was involved in this process,
cells treated with 50𝜇M of WY-14643 or vehicle were sub-
jected to 20 h of hypoxia, and ROS level was measured by
DCF florescence. Hypoxia increased ROS generation (𝑃 <
0.05 versus control) and WY-14643 attenuated hypoxia-
induced increase in ROS (𝑃 < 0.05 versus hypoxia). In
cells transfected with UCP3 siRNA, WY-14643 treatment did
not reduce hypoxia-induced ROS generation (𝑃 < 0.05
versus control, Figure 4(a)). Lucigenin-amplified chemilu-
minescence showed that WY-14643 diminished hypoxia-
induced increase in intracellular ROS generation and deple-
tion of UCP3 by siRNA abrogated the reduction of ROS with
WY-14643 treatment (Figure 4(b)). For selective detection
of mitochondrial superoxide, cells treated with 50𝜇M of
WY-14643 or vehicle were subjected to 20 h of hypoxia
and MitoSOX Red-based flow cytometry was performed.
Hypoxia increased mitochondrial superoxide generation
(𝑃 < 0.05 versus control) andWY-14643 attenuated hypoxia-
induced increase in mitochondrial superoxide (𝑃 < 0.05
versus hypoxia). In cells transfected with UCP3 siRNA,
WY-14643 treatment did not reduce hypoxia-induced mito-
chondrial superoxide generation (𝑃 < 0.05 versus control,
Figure 4(c)).
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Figure 3: WY-14643 increased UCP3 expression in H9c2 cells. (a) Treatment of WY-14643 at 50 𝜇M increased expression of PPAR𝛼 target
gene PDK4 mRNA and expression of PPAR𝛾 target gene aP2 was not altered after the treatment of WY-14643. (b) Quantitative PCR shows
that WY-14643 treatment at 10, 50, and 100𝜇M for 24 h increased mRNA levels of UCP3 compared with vehicle treatment. ∗𝑃 < 0.05 versus
WY-14643 0 𝜇M (𝑛 = 3). (c) RT-PCR shows increased UCP3 mRNA expression following WY-14643 treatment. (d) Western blot of UCP3
shows increased protein level after WY-14643 treatment. (e) Treatment of WY-14643 at 50𝜇M also increased phosphorylation of Akt and
STAT3 and protein level of HO-1 as well as UCP3. Representative blots from three independent experiments are shown. Band intensities were
quantified using an image analyzer, normalized by expression levels of 𝛽-actin, and fold changes are plotted under each band. (f) Transfection
of UCP3 siRNA silenced UCP3 mRNA (#2, #4, and #5). (g) Western blot of UCP3 shows that transfection of UCP3 siRNA downregulated
UCP3 protein level. #5 was used for further experiment. WY: WY-14643. Rosi: rosiglitazone. HO-1: heme oxygenase-1. SC: scramble.
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Figure 4: WY-14643 decreased hypoxia-stimulated intracellular ROS production. (a) Cells treated with 50 𝜇M of WY-14643 or vehicle were
subjected to 20 h of hypoxia and ROS level was measured by DCF fluorescence. Hypoxia increased ROS generation andWY-14643 attenuated
hypoxia-induced increase in ROS. UCP3 siRNA abrogated the effect of WY-14643 on ROS production. ∗𝑃 < 0.05 versus control. #𝑃 < 0.05
versus hypoxia (𝑛 = 3). (b) Cells treated with 50 𝜇M of WY-14643 or vehicle were subjected to 20 h of hypoxia and ROS level was measured
by lucigenin-amplified chemiluminescence. Hypoxia increased ROS generation andWY-14643 attenuated hypoxia-induced increase in ROS.
UCP3 siRNA abrogated the effect of WY-14643 on ROS production (𝑛 = 3). (c) Cells treated with 50 𝜇M of WY-14643 or vehicle were
subjected to 20 h of hypoxia and mitochondrial superoxide was measured by MitoSOX Red fluorescence. Hypoxia increased mitochondrial
superoxide generation and WY-14643 attenuated hypoxia-induced increase in mitochondrial superoxide. UCP3 siRNA abrogated the effect
of WY-14643 on mitochondrial superoxide production. ∗𝑃 < 0.05 versus control. #𝑃 < 0.05 versus hypoxia (𝑛 = 3). Hyp: hypoxia; WY:
WY-14643 treatment.
3.6. Cell Survival against Hypoxia-Reoxygenation Injury. Cell
survival experiments were conducted to evaluate the pro-
tective effect of WY-14643 against hypoxia-reoxygenation
(HR) injury. H9c2 cells incubated in control medium or
experimental media treated with 0.1 to 100𝜇M of WY-
14643 for 24 h were subjected to 20 h of hypoxia and 2 h of
reoxygenation prior toMTT assay.WY-14643 treatment at 10,
50, and 100 𝜇Mdecreased cell death afterHR (𝑃 < 0.05 versus
control, Figure 5). To examine the role of UCP3 inWY-14643
induced protection, cell survival experiment was also con-
ducted in cells transfected with UCP3 siRNA. Cell protective
effect of 50𝜇M of WY-14643 against HR was diminished
in cells transfected with UCP3 siRNA (𝑃 < 0.05 versus
control, Figure 6(a)). Treatment of PI3 K inhibitor Wort-
mannin 100 nM, MEK inhibitor PD98059 50 𝜇M, or HO-1
inhibitor zinc protoporphyrin-IX 100 nM also decreased the
protective effect of WY-14643 (𝑃 < 0.05 versus control).
The degrees of decrease in cell survival following treatment
with the above inhibitors were significantly less compared
with that in cells transfected with UCP3 siRNA (𝑃 <
0.05 versus HR (+), WY-14643 (+), and UCP3 siRNA (+),
Figure 6(b)).
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Figure 5: H9c2 cells treated with WY-14643 were more resistant
against hypoxia-reoxygenation injury. Cells were incubated with
medium containing 0 to 100 𝜇M of WY-14643 for 24 h before 20 h
of hypoxia and 2 h of reoxygenation. MTT assay shows that cell
viabilitywas increasedwith treatment ofWY-14643 10 𝜇Mor greater.
∗
𝑃 < 0.05 versus WY-14643 0 𝜇M (𝑛 = 3). ∗𝑃 < 0.05 versus WY-
14643 0 𝜇M (𝑛 = 3). HR: hypoxia-reoxygenation.
4. Discussion
In the current study, administration of WY-14643, a PPAR𝛼
agonist, reduced myocardial infarct size following ischemia-
reperfusion injury in rats. Treatment of WY-14643 in
H9c2 cell line improved cell survival against hypoxia-
reoxygenation. Activation of PPAR𝛼 by WY-14643 was asso-
ciated with increased expression of UCP3 in vitro and in
vivo, which resulted in attenuation of ROS production.
Furthermore, depletion of UCP3 by siRNA abolished the
protective effect of WY-14643, implicating a critical role of
UCP3 in PPAR𝛼-mediated cardioprotection.
PPAR𝛼 is well known to be involved in myocardial
fatty acid and glucose metabolism. It was demonstrated that
cardiac specific PPAR𝛼-overexpression increasedmyocardial
fatty acid uptake and oxidation and concomitantly decreased
glucose uptake and oxidation [2].Thesemetabolic alterations
were associated with ventricular hypertrophy and contractile
dysfunction, which was improved by low triglyceride diet [2,
4]. PPAR𝛼-overexpressed mice also showed impaired recov-
ery of myocardial function following ischemia-reperfusion
injury [18]. These data suggest that chronic activation of
PPAR𝛼might be detrimental to cardiac function.On the con-
trary, acute activation of PPAR𝛼 by pharmacologic agonists
demonstrated cardioprotection against ischemia-reperfusion
injury [5–7, 19] while the underlying mechanisms or molec-
ular targets involved in PPAR𝛼-mediated cardioprotection
have not been fully elucidated yet.
It was proposed that cardioprotection by PPAR𝛼 might
bemediated throughmetabolic and anti-inflammatory effect.
PPAR𝛼 agonist inhibited proinflammatory cytokine produc-
tion and matrix metalloproteinase expression and activa-
tion of NF-𝜅B [5]. In accordance with the findings from
PPAR𝛼-overexpressed mice, increased fatty acid oxidation
with concomitantly decreased glucose oxidation was also
observed in rodents treated with PPAR𝛼 agonist com-
pared with vehicle after acute ischemia-reperfusion injury
[5]. Although elevated serum free fatty acid concentration
is known to aggravate myocardial infarction [20], given
that PPAR𝛼-overexpressed mice showed systolic dysfunction
with cardiac metabolic fuel shift, direct causal relationship
between altered cardiac metabolism and cardioprotection
against acute ischemia-reperfusion injury is still unclear.
Othermechanisms including activation of the phosphatidyli-
nositol 3-kinase/Akt and nitric oxide signaling pathway were
also suggested [6, 7].
ROS is a critical mediator of ischemia-reperfusion injury
[21]. Mitochondrial electron transport system is one of the
major sources of cellular ROS generation. Return of oxygen
supply during reperfusion induces large burst of ROS. Lipid
peroxidation resulted from ROS breakdown of cell mem-
branes. In addition, ROS trigger mitochondrial permeability
transition pore opening, which causes loss of mitochondrial
inner membrane potential and ceased ATP production and
initiation of apoptosis [22]. Since mitochondria are major
targets of damage fromROS as well as a source of production,
reducing ROS burst during reperfusionmay be important for
maintaining mitochondrial function and cardioprotection.
The production of ROS is proportional to mitochondrial
membrane potential, and mild uncoupling of mitochondrial
respiration is thought to reduce ROS production [23].
UCPs are inner mitochondrial carrier proteins that
induce proton leak and dissipate the mitochondrial elec-
trochemical gradient [8] and were suggested to exert a
protective role during oxidative stress in previous studies.
Indeed, UCP2 overexpression in rat neonatal cardiomyocyte
increased viability against oxidative stress via reduced ROS
production and mitochondrial Ca2+ overload [13]. Pharma-
cologic uncoupling agents such as dinitrophenol also con-
ferred cardioprotective effect [11, 12, 24]. Recently, a crucial
role of UCP3 in protection against myocardial ischemia-
reperfusion injury was demonstrated in a cardiac UCP3
knockout mouse model [25]. Despite the fact that PPAR𝛼
regulate UCPs levels, the influence of PPAR𝛼 on UCPs
and resultant ROS generation during myocardial ischemia-
reperfusion has not been elucidated heretofore.
In the current study, treatment of WY-14643, a PPAR𝛼
ligand, upregulated the expression of UCP3, attenuated ROS
production, and improved cell survival against hypoxia-
reoxygenation. While WY-14643 also increased phosphory-
lation of kinases known to be involved in cardioprotective
signaling pathways, protective effects of WY-14643 were
nearly completely attenuated in cells transfected with UCP3
siRNA, which suggests that UCP3 may play a central role in
cardioprotective effect of PPAR𝛼 activation. Since we have
not shown whether knockdown of UCP3 also has an effect
on phosphorylation of Akt and STAT3, it cannot be excluded
that UCP3-induced cardioprotective effect of WY-14643 may
involve the subsequent phosphorylation of cardioprotective
kinases. As signaling ROS is known to be an important medi-
ator in ischemic preconditioning [26] and upregulation of
UCPs was also shown during ischemic preconditioning [14],
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Figure 6: Depletion of UCP3 abrogated cell protective effect of WY-14643. Cells were incubated with medium containing 50𝜇M of WY-
14643 for 24 h before 20 h of hypoxia and 2 h of reoxygenation. (a) MTT assay shows that cell viability was increased with treatment of
WY-14643 50 𝜇M while the enhanced viability was attenuated in cells transfected with UCP3 siRNA. ∗𝑃 < 0.05 versus control (𝑛 = 3). (b)
Wortmannin, PD98059, or zinc protoporphyrin-IX (ZnPP IX) decreased protective effect ofWY-14643.Mitigated cell survival with treatment
ofWortmannin, PD98059, or ZnPP IXwas less significant comparedwith that of cells transfectedwithUCP3 siRNA. ∗𝑃 < 0.05 versus control;
#
𝑃 < 0.05 versus HR (+), WY-14643 (+), and UCP3 siRNA (+) (𝑛 = 3). HR: hypoxia-reoxygenation.
cardioprotection by PPAR𝛼 activationmay be associatedwith
UCP-mediated mild uncoupling and subsequent increase in
signaling ROS in resting cardiomyocytes.
Previous studies indicated that cardiac UCP3 level is
regulated by PPAR𝛼 [15, 16]. In contrast to UCP3, UCP2
mRNA and protein levels were not affected by administration
of PPAR𝛼 ligand in the current study. Normally, level of
transcripts for UCP2 is more dominant than UCP3 in the
rat heart [27]. The exact physiologic roles of UCP2 or UCP3
in intact heart are not yet completely understood. However,
ectopic overexpression of UCP1 in mouse heart was also
shown to improve the severity of ischemia-reperfusion injury
[28]. Thus, it may be speculated that both UCP2 and UCP3,
once activated during ischemia-reperfusion, can contribute
to reduced ROS generation.
Reperfusion injury can be manifested by myocardial
stunning or arrhythmia as well as myocardial infarction.
ROS play a significant role in the development of myocar-
dial stunning, a reversible contractile dysfunction following
reperfusion [29] and arrhythmias [30]. Stability of the inner
mitochondrial membrane potential is closely associated with
reperfusion-induced arrhythmias [31]. Treatment of WY-
14643 reduced the incidence of arrhythmia in the current
study. In addition, there were trends towards higher mean
arterial pressure and rate pressure product in rats that
received WY-14643 during the early phase of reperfusion
without statistical significance. Activation ofUCPmight have
detrimental impact onmyocardial contractility since increase
in uncoupled respiration can lower mitochondrial ATP pro-
duction. Indeed, increased UCP expression was observed in
the failing human heart [32]. In acute ischemia-reperfusion,
however, it might be possible that inefficiency in energy pro-
duction is overcome with benefits of reduced oxidative stress.
Clinically, fibrates are synthetic PPAR𝛼 agonists widely
used to treat dyslipidemia. Fibrates stimulate fatty acid oxida-
tion, improve lipoprotein metabolism, and exert antiathero-
genic effect by decreasing vascular inflammation via PPAR𝛼
activation [33]. Fibrates have been shown to be effective in
prevention of cardiovascular events, particularly coronary
disease [34]. Results of our study are in accordance with pre-
vious studies demonstrating beneficial effect of PPAR𝛼 acti-
vation and suggest a possible role of PPAR𝛼 agonists as a ther-
apeutic agent for acute ischemia-reperfusion injury as well.
In conclusion, administration of PPAR𝛼 agonist WY-
14643 decreased the degree ofmyocardial infarction and inci-
dence of reperfusion-induced arrhythmia. PPAR𝛼 activation
byWY-14643 conferred cytoprotective effect against hypoxia-
reoxygenation. The current study also provides primary
evidence regarding the underlying protective mechanism
of WY-14643 that involves increased UCP3 expression and
resultant attenuation of ROS production.
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